Tissue Repair Peptides (BPC-157, TB-500, GHK-Cu) — References

Mirrored Reference Dossier

Parent Topic: Tissue Repair Peptides (BPC-157, TB-500, GHK-Cu) | References Hub: 02 - Compounds & Molecules References MOC

---

Landmark Peer-Reviewed Studies

1. Chang et al. (2011) — Journal of Applied Physiology

• Citation: Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. S. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774–780.
• Identifiers: PMID: 21030672 (PubMed · Europe PMC) | DOI: 10.1152/japplphysiol.00945.2010 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Ex vivo rat Achilles tendon explant culture, transwell filter migration assay, and Western blot phosphorylation analysis.
• Key Quantitative Outcomes: BPC-157 significantly accelerated tendon fibroblast outgrowth from tendon explants ($p<0.05$), increased transwell tenocyte migration speed in a dose-dependent manner ($+2.3\text{-fold}$ at $2\mu \text{g/mL}$, $p<0.01$), protected tenocytes against ${\text{H}}_2{\text{O}}_2$-induced apoptosis ($p<0.01$), and increased phosphorylation of Focal Adhesion Kinase (FAK) by $+70\%$ and paxillin by $+60\%$ without altering total protein levels.

2. Chang et al. (2014) — Molecules

• Citation: Chang, C. H., Tsai, W. C., Hsu, Y. H., & Pang, J. H. S. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules, 19(11), 19066–19077.
• Identifiers: PMID: 25415472 (PubMed · Europe PMC) | PMCID: PMC6271067 (PMC Full Text) | DOI: 10.3390/molecules191119066 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Quantitative RT-PCR, immunocytochemistry, and Western blot analysis of primary Achilles tendon fibroblasts treated with BPC-157 ($0.1\text{–}0.5\mu \text{g/mL}$) and Growth Hormone.
• Key Quantitative Outcomes: BPC-157 alone did not directly force cell proliferation in vitro, but upregulated Growth Hormone Receptor (GHR) mRNA and protein expression on tendon fibroblasts by up to $7\text{-fold}$ ($p<0.001$) over 3 days and increased downstream JAK2 phosphorylation when exposed to Growth Hormone, explaining the potent in vivo synergy between BPC-157 and endogenous/secretagogue GH pulses.

3. Pickart & Margolina (2018) — International Journal of Molecular Sciences

• Citation: Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987.
• Identifiers: PMID: 29986520 (PubMed · Europe PMC) | PMCID: PMC6073405 (PMC Full Text) | DOI: 10.3390/ijms19071987 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Transcriptomic analysis using the Broad Institute Connectivity Map (CMap) across $13,424$ human genes alongside synthesis of human clinical dermal and wound-healing studies.
• Key Quantitative Outcomes: Demonstrated that GHK-Cu alters the expression of $31.2\%$ of all human genes ($\ge 50\%$ up- or down-regulation across $4,096$ genes), including upregulation of 47 DNA repair genes (downregulating only 5), suppression of 70% of pro-metastatic/pro-inflammatory genes (such as NF-$\kappa$B and TNF-$\alpha$), and restoration of COPD lung fibroblast collagen contraction and TGF-$\beta$ signaling. In 12-week human facial clinical trials ($n=71$), GHK-Cu cream increased dermal collagen production in $70\%$ of women (outperforming Vitamin C at $50\%$ and retinoic acid at $40\%$).

4. Philp et al. (2004) / Goldstein et al. (2012) — Expert Opinion on Biological Therapy (Thymosin $\beta 4$)

• Citation: Goldstein, A. L., Hannappel, E., Sosne, G., & Kleinman, H. K. (2012). Thymosin $\beta 4$: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 12(1), 37–51.
• Identifiers: PMID: 22074294 (PubMed · Europe PMC) | DOI: 10.1517/14712598.2012.634793 (DOI · SciDB · Scholar)
• Study Design & Sample Size: Translational and Phase II human clinical trial synthesis of Thymosin $\beta 4$ (TB4 / TB-500) in dermal ulcers, corneal neurotrophic keratitis, and myocardial ischemia.
• Key Quantitative Outcomes: Confirmed that Thymosin $\beta 4$ sequesters G-actin, increases endothelial cell migration by $4\text{- to }6\text{-fold}$, activates epicardial progenitor cells and Akt survival signaling post-ischemia, and in Phase II human venous stasis/pressure ulcer trials accelerated complete wound closure rates at days 30–84 across topical and systemic regimens.